February 2020 Volume 16, Issue 2
Volume 16, Issue 2 | February 2020
February 2020
In this Issue
Research & Development
Cracking the code of gene regulation
Queen's University Belfast researchers look into how and why only certain DNA elements are chosen to regulate gene expression, and how this predisposes us to diseasesThe benefits of B cells
Multiple studies point to B cells’ role in promoting anti-tumor immunity‘A leading-edge preclinical testing method’
Intestine-on-a-Chip promises better personalized medicineRas, Raf and recall
Scripps Research team uncovers the genes that play a role in cementing experiences as long-term memoriesNew uses for Ryanodex
Eagle and UPenn explore drug's potential to treat Alzheimer’sDiscovery
Making gold out of lead
UC San Diego team identifies the molecule that allows Zika to enter brain cells—a discovery that could also lead to a new way to target brain cancer cellsProprietary platform
Lodo reinvents environmentally sourced, natural product drug discoveryPartnering for pulmonary disease
Rare disease-focused companies link up to identify, develop therapeuticsCan baldness be stopped?
Mount Sinai shares new information regarding the dermal sheath found around hair folliclesClinical Trials
A competitor for Cosentyx
AbbVie and Boehringer Ingelheim's Skyrizi showed superiority to Novartis' Cosentyx in Phase 3 trial of plaque psoriasisGood news from HARMONY
ACADIA’s pimavanserin halts trial at interim analysis after meeting primary endpointFull steam ahead in FSHD
Fulcrum advances losmapimod into Phase 2b trialRiding success to autoimmune disease
Moderna follows clinical validation of systemic delivery with two more development candidatesCodexis and Nestlé Health Science team up
Companies look to advance GI therapeutic candidate CDX-7108Diagnostics
Finding mutations, matching treatments
Clinical trial indicates that blood test beats biopsies for breast cancerAnalysis pairs up with immunotherapy
Shimadzu and Providence Cancer Institute team up to advance cancer immunotherapy researchWhy wait?
Bio-Rad’s ddPCR technology provides faster, more accurate diagnosesAdvancing genomics
Illumina announces new sequencing system, partnership with Roche and a software suite to accelerate genomics adoptionFurther into oncology and NGS
NeoGenomics acquires oncology operation from Human Longevity for $37 millionFeature
News Roundup: Coronavirus
Recent news about research into diagnosis and treatment of the Wuhan coronavirusFocus Feature: Tox Screening
A looks at recent action in the world of toxicology screening, including recent news and a Q&A with Taconic BiosciencesAnalytica 2020 Show Preview: Aiming for excellence in analysis
Science meets industry at the biennial Analytica conference, which will be held in Munich March 31 through April 03Commentary
Commentary: Learning from the Wuhan coronavirus
Collaboration leads the way to better understanding of pathogenEverything is too expensive: Part 2
Peter Kissinger follows up his December column with a "part 2" talking about the cost-benefit ratio in the life sciencesEditor's Focus
Editor’s Focus: Breaking down the outbreak
The Wuhan coronavirus is something to be concerned about, but like every outbreak we need to keep things in perspectiveBusiness & Government Policy
MorphoSys and Incyte sign collaboration and license deal
Agreement focuses on tafasitamab for the treatment of B cell malignanciesOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsThe EMA and the U.K. after Brexit
United Kingdom withdrawal from European Union changes dynamicsTargets acquired
A look at a few recent acquisition deals in the pharma worldContract Services
Change continues for CDMOs
Capstone Headwaters report highlights increased growth, transactions in pharmaceutical outsourcingProviding better service for vesicles analysis
Exosomics implements NanoFCM’s NanoAnalyzer at its Siena siteDeepening DMPK at Sygnature
Company development also bolsters subsidiary’s kidney disease and fibrosis capabilitiesTrial success a priority for new alliance
Syneos Health and AiCure announce partnership to optimize patient engagementPreclinical
Targeting cancer with Claudin 6
BioNTech announces publication of preclinical data for a CARVac targeting Claudin 6Activating innate immunity against breast cancer
Silverback Therapeutics’ SBT6050 shows promise in HER2-expressing tumorsReversing resistance
Drug can affect non-Hodgkin’s lymphoma cell lines
